SEC Fines Biopharma Co. Execs Over Hidden FDA Findings
Former executives of Spero Therapeutics will pay over $187,000 to settle the U.S. Securities and Exchange Commission's claims they downplayed the likelihood that the U.S. Food and Drug Administration would reject...To view the full article, register now.
Already a subscriber? Click here to view full article